Menu Search
Equities

Oncolys Biopharma Inc

4588:TYO

Oncolys Biopharma Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)582.00
  • Today's Change11.00 / 1.93%
  • Shares traded278.30k
  • 1 Year change-15.04%
  • Beta1.1933
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Oncolys Biopharma Inc's revenues fell -93.54% from 976.18m to 63.04m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 1.15bn to a larger loss of 1.94bn.
Gross margin0.00%
Net profit margin-5,813.82%
Operating margin-5,876.45%
Return on assets-97.25%
Return on equity-134.78%
Return on investment-116.54%
More ▼

Cash flow in JPYView more

In 2023, cash reserves at Oncolys Biopharma Inc fell by 178.44m. Cash Flow from Financing totalled 1.14bn or 1,812.47% of revenues. In addition the company used 1.34bn for operations while cash used for investing totalled 5.39m.
Cash flow per share-94.19
Price/Cash flow per share--
Book value per share67.90
Tangible book value per share67.90
More ▼

Balance sheet in JPYView more

Oncolys Biopharma Inc appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio7.03
Quick ratio7.01
Total debt/total equity0.2582
Total debt/total capital0.2052
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.